Journal article · 2023 · Open access
Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development
Frontiers in Immunology, 14, 1151888 · Published 12 May 2023 · DOI 10.3389/fimmu.2023.1151888
In brief
“Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development” is a 2023 journal article by Zuben E. Sauna and 3 co-authors, published in Frontiers in Immunology. OpenAlex counts 25 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 25
- Most cited in
- 2026 (10)
- Field-weighted impact
- 2.36
- Authors
- 4
Abstract
Immunogenicity continues to pose a challenge in the development of biotherapeutics like conventional therapeutic-proteins and monoclonal antibodies as well as emerging modalities such as gene-therapy components, gene editing, and CAR T cells. The approval of any therapeutic is based on a benefit-risk evaluation. Most biotherapeutics address serious medical conditions where the standard of care has a poor outcome. Consequently, even if immunogenicity limits the utility of the therapeutic in a sub-set of patients, the benefit-risk assessment skews in favor of approval. Some cases resulted in the discontinuation of biotherapeutics due to immunogenicity during drug development processes, This special issue presents a platform for review articles offering a critical assessment of accumulated knowledge as well as novel findings related to nonclinical risks that extend our understanding of the immunogenicity of biotherapeutics. Some of the studies in this collection leveraged assays and methodologies refined over decades to support more clinically relevant biological samples. Others have applied rapidly advancing methodologies in pathway-specific analyses to immunogenicity. Similarly, the reviews address urgent issues such as the rapidly emerging cell and gene therapies which hold immense promise but could have limited reach as a significant number of the patient population could potentially not benefit due to immunogenicity. In addition to summarizing the work presented in this special issue we have endeavored to identify areas where additional studies are required to understand the risks of immunogenicity and develop appropriate mitigation strategies.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Sauna, Z. E., Jawa, V., Balu‐Iyer, S. V., & Chirmule, N. B. (2023). Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development. Frontiers in Immunology, 14, 1151888. https://doi.org/10.3389/fimmu.2023.1151888
MLA 9
Sauna, Zuben E., et al. “Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development.” Frontiers in Immunology, vol. 14, 2023, p. 1151888. https://doi.org/10.3389/fimmu.2023.1151888.
Chicago
Sauna, Zuben E., Vibha Jawa, Sathy V. Balu‐Iyer, and Narendra B. Chirmule. 2023. “Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development.” Frontiers in Immunology 14: 1151888. https://doi.org/10.3389/fimmu.2023.1151888.
Harvard
Sauna, Z. E. et al. (2023) ‘Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development’, Frontiers in Immunology, 14, p. 1151888. doi:10.3389/fimmu.2023.1151888.
IEEE
Z. E. Sauna, V. Jawa, S. V. Balu‐Iyer, and N. B. Chirmule, “Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development,” Frontiers in Immunology, vol. 14, p. 1151888, 2023, doi: 10.3389/fimmu.2023.1151888.
BibTeX
@article{sauna2023understanding,
title = {{Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development}},
author = {Sauna, Zuben E. and Jawa, Vibha and Balu‐Iyer, Sathy V. and Chirmule, Narendra B.},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
pages = {1151888},
doi = {10.3389/fimmu.2023.1151888},
url = {https://doi.org/10.3389/fimmu.2023.1151888}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 1 | |
| 2024 | 7 | |
| 2025 | 7 | |
| 2026 | 10 |
Its field-weighted citation impact is 2.36: it has been cited 2.36 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- immunogenicity
- biologic therapy
- monoclonal antibodies
- therapeutic proteins
- gene therapy
- genome editing
- chimeric antigen receptor T cells
- cell and gene therapy
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Sauna, Z. E., Jawa, V., Balu‐Iyer, S. V., & Chirmule, N. B. (2023). Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development. Frontiers in Immunology, 14, 1151888. https://doi.org/10.3389/fimmu.2023.1151888
How many times has this paper been cited?
25 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Zuben E. Sauna, Vibha Jawa, Sathy V. Balu‐Iyer, Narendra B. Chirmule.
What is the DOI of this paper?
10.3389/fimmu.2023.1151888, permanently at https://doi.org/10.3389/fimmu.2023.1151888. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.